Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a 23-valent pneumococcal polysaccharide vaccine in healthy participants aged 2 years and older
CTR20232347Phase 3Active
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Sep 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by AIM Vaccine Co., Ltd.. Started Sep 2023; status: active.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20232347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232347.